Debt-to-equity in % of Poseida Therapeutics, Inc. from Q1 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Poseida Therapeutics, Inc. quarterly Debt-to-equity history and change rate from Q1 2021 to Q3 2024.
  • Poseida Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2024 was 236%, a 121% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Poseida Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2024 236% +129% +121% 30 Sep 2024
Q2 2024 205% +115% +127% 30 Jun 2024
Q1 2024 150% +51% +51% 31 Mar 2024
Q4 2023 125% +18% +17% 31 Dec 2023
Q3 2023 107% +3% +3.1% 30 Sep 2023
Q2 2023 90% -16% -15% 30 Jun 2023
Q1 2023 100% +19% +23% 31 Mar 2023
Q4 2022 107% +45% +74% 31 Dec 2022
Q3 2022 104% +50% +95% 30 Sep 2022
Q2 2022 107% +62% +138% 30 Jun 2022
Q1 2022 81% +7% +8.9% 31 Mar 2022
Q4 2021 62% 31 Dec 2021
Q3 2021 53% 30 Sep 2021
Q2 2021 45% 30 Jun 2021
Q1 2021 74% 31 Mar 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.